United States - English - NLM (National Library of Medicine)

washington homeopathic products - astragalus - to relieve the symptoms of weakness. indications:  astragalus   weakness if symptoms persist/worsen or if pregnant/nursing, consult your practitioner.

Singapore - English - HSA (Health Sciences Authority)

dentsply sirona singapore pte ltd - dental - intended for both one-and two-stage surgical procedures in the following situations and with the clinical protocols: replacing missing teeth in single or multiple unit applications in the mandible or maxilla -immediate placement in extraction sites and in situations with partially or completely healed alveolar ridge -especially indicated for use in soft bone applications where implants with other implant surface treatments may be less effective -immediate & early loading for all indications except in single tooth situations on implant shorter than 8mm or in soft bone (type iv)where implant stability may be difficult to obtain & immediate loading may not be appropriate. intended use for osseospeed ev3.0s is limited to placement of maxillary lateral incisors & mandibular incisors. osseospeed profile ev4.2&4.8 are to be used only together with profile ev restorative components,implant driver profile ev, radiographic implant guides profile ev & non-indexed prosthetic components within astra tech implant system ev.

European Union - English - EMA (European Medicines Agency)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - vaccines - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older.the use of this vaccine should be in accordance with official recommendations.

Israel - English - Ministry of Health

astrazeneca (israel) ltd - esomeprazole - tablets - esomeprazole 20 mg - esomeprazole - esomeprazole - nexium tablets are indicated in adults for:gastroesophageal reflux disease (gerd)- treatment of erosive reflux esophagitis- long-term management of patients with healed esophagitis to prevent relapse- symptomatic treatment of gastroesophageal reflux disease (gerd)in combination with an appropriate antibacterial therapeutic regimen for the eradication of helicobacter pylori and:- healing of helicobacter pylori associated duodenal ulcer and- prevention of relapse of peptic ulcers in patients with helicobacter pylori associated ulcers.patients requiring nsaid therapy- healing of gastric ulcers associated with nsaid therapy. - prevention of gastric and duodenal ulcers associated with nsaid therapy in patients at risk.prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers.nexium 20 mg tablets are indicated in adolescents from the age of 12 years forgastroesophageal reflux disease (gerd)- treatment of erosive reflux esophagitis- long-term management of patients with healed esophagi

Israel - English - Ministry of Health

astrazeneca (israel) ltd - esomeprazole - tablets - esomeprazole 40 mg - esomeprazole - esomeprazole - nexium tablets are indicated in adults for:gastroesophageal reflux disease (gerd)- treatment of erosive reflux esophagitis- long-term management of patients with healed esophagitis to prevent relapse- symptomatic treatment of gastroesophageal reflux disease (gerd)in combination with an appropriate antibacterial therapeutic regimen for the eradication of helicobacter pylori and:- healing of helicobacter pylori associated duodenal ulcer and- prevention of relapse of peptic ulcers in patients with helicobacter pylori associated ulcers.patients requiring nsaid therapy- healing of gastric ulcers associated with nsaid therapy. - prevention of gastric and duodenal ulcers associated with nsaid therapy in patients at risk.prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers.nexium 40 mg tablets are indicated in adolescents from the age of 12 years for;gastroesophageal reflux disease (gerd)- treatment of erosive reflux esophagitis

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - goserelin, quantity: 3.6 mg - implant - excipient ingredients: polyglactin - prostate cancer: palliative treatment of metastatic or locally advanced prostate cancer, where suitable for hormonal manipulation. adjuvant and neo-adjuvant therapy in combination with radiotherapy for the management of locally advanced prostate cancer in men suitable for hormonal manipulation. breast cancer: treatment of advanced breast cancer (t3b, t4 or any t with n2, 3 or m plus) in premenopausal women suitable for hormonal manipulation. adjuvant therapy in early breast cancer, in pre- and perimenopausal women suitable for hormonal manipulation. endometriosis: in the management of visually proven endometriosis to reduce symptoms including pain and the size and number of endometrial lesions. uterine fibroids: in the management of fibroids, astrazeneca goserelin shrinks the lesions and reduces the symptoms, including pain. astrazeneca goserelin also increases the haemoglobin concentration and haematocrit in women with anaemia attributable to menorrhagia. it is used as an adjunct to surgery to facilitate the operative technique and reduce operativeblood loss. endometrial thinning: use as an endometrial thinning agent prior to endometrial ablation. assisted reproduction: pituitary down regulation in preparation for controlled ovarian superstimulation.

United States - English - NLM (National Library of Medicine)

bioactive nutritional, inc. - astragalus propinquus root (unii: 922op8yupf) (astragalus propinquus root - unii:922op8yupf), echinacea angustifolia (unii: vb06av5us8) (echinacea angustifolia - unii:vb06av5us8), goldenseal (unii: zw3z11d0jv) (goldenseal - unii:zw3z11d0jv), smilax regelii root (unii: 2h1576d5wg) (sarsaparilla - unii:2h1576d5wg), tabebuia impetiginosa bark (unii: 6gla1946wx) (tabebuia impetiginosa bark - unii:6gla1946wx), sus scrofa thyroid (unii: 6rv024oauq) (sus scrofa thyroid - unii:6rv024oauq), gold (unii: 79y1949pyo) ( - astragalus propinquus root 3 [hp_x] in 1 ml - for temporary relief of chills up and down back; extremities heavy, ache at night; general exhaustion; dry, hard cough with weakness in the chest. for temporary relief of chills up and down back; extremities heavy, ache at night; general exhaustion; dry, hard cough with weakness in the chest.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

bodhi bio tech sdn bhd - rehmannia glutinosa; lycium barbarum; ligusticum chuanxiong; poria cocos; dimocarpus longan; morinda officinalis; astragalus membranaceus; spatholobus suberectus; paeonia lactiflora; atractylodes macrocephala; glycyrrhiza uralensis; scutellaria baicalensis; coptis chinensis; anemarrhena asphodeloides; astragalus membranaceus; angelica sinensis; codonopsis pilosula; equus asinus; panax ginseng; cinnamomum cassia; ligusticum chuanxiong; spatholobus suberectus; morinda officinalis; atractylodes macrocephala; p -

United States - English - NLM (National Library of Medicine)

astrazeneca pharmaceuticals lp - azd-1222 (unii: b5s3k2v0g8) (azd-1222 - unii:b5s3k2v0g8) -

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - chadox1-s, quantity: 100000000000 vp/ml - injection, solution - excipient ingredients: histidine; magnesium chloride hexahydrate; sucrose; disodium edetate; polysorbate 80; sodium chloride; histidine hydrochloride monohydrate; ethanol absolute; water for injections - vaxzevria has provisional approval for the indication:,active immunisation of individuals greater than or equal to 18 years old for the prevention of coronavirus disease 2019 (covid-19) caused by sars-cov-2.,the use of this vaccine should be in accordance with official recommendations.,the decision has been made on the basis of short term efficacy and safety data. continued approval is dependent upon the evidence of longer-term efficacy and safety from ongoing clinical trials and post-market assessment.